M&T Bank’s Agios Pharmaceuticals AGIO Stock Holding History

M&T Bank’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-1,000	Closed	-$10K	–	2091
2015 Q1	$10K	Hold	1,000	–	–	﹤0.01%	2001
2014 Q4	$21K	Buy	+1,000	New	+$89.3K	﹤0.01%	1995

Other funds holding AGIO

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

M&T Bank's AGIO Position: Q2 2020 in Review

M&T Bank sold out of Agios Pharmaceuticals (AGIO) in Q2 2020, closing a stake of 300 shares — an estimated $10.6M sold.

M&T Bank first reported a position in AGIO in Q3 2014 and held it in 12 quarters. The position peaked at $10.6M in Q1 2020. 216 funds tracked by Wall St. Rank hold AGIO as of Q2 2020.

M&T Bank reported no remaining Agios Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
M&T Bank sold 300 Agios Pharmaceuticals shares in Q2 2020, an estimated $10.6M.
M&T Bank first reported a position in Agios Pharmaceuticals in Q3 2014 and held it in 12 quarters.
M&T Bank's Agios Pharmaceuticals position peaked at $10.6M in Q1 2020.
216 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2020.

Based on M&T Bank's 13F filing for Q2 2020, filed 29 Jul 2020.